198 related articles for article (PubMed ID: 36342081)
21. Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R; Hansen J; Pelzer BW; Nieper P; Lohmann T; Kisis I; Riet T; Kohlhas V; Nguyen PH; Peifer M; Abedpour N; Bosco G; Thomas RK; Kochanek M; Knüfer J; Jonigkeit L; Beleggia F; Holzem A; Büttner R; Lohneis P; Meinel J; Ortmann M; Persigehl T; Hallek M; Calado DP; Chmielewski M; Klein S; Göthert JR; Chapuy B; Zevnik B; Wunderlich FT; von Tresckow B; Jachimowicz RD; Melnick AM; Reinhardt HC; Knittel G
Blood Cancer Discov; 2023 Jan; 4(1):78-97. PubMed ID: 36346827
[TBL] [Abstract][Full Text] [Related]
22. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
23. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
24. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy.
Tyagi A; Abrari A; Khurana A; Tyagi S
J Cancer Res Ther; 2022; 18(4):1129-1136. PubMed ID: 36149172
[TBL] [Abstract][Full Text] [Related]
26. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
27. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
28. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
29. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
[TBL] [Abstract][Full Text] [Related]
30. Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay.
Ta R; Santini C; Gou P; Lee G; Tai YC; O'Brien C; Fontecha M; Grant C; Bacon L; Finn S; Vandenberghe E; Quinn F; Dua R; Flavin R
J Mol Diagn; 2021 Mar; 23(3):323-340. PubMed ID: 33385586
[TBL] [Abstract][Full Text] [Related]
31. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
[TBL] [Abstract][Full Text] [Related]
32. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
33. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
34. Genomic Alterations and MYD88
Jiang S; Qin Y; Gui L; Liu P; Jiang H; Liu B; Yang J; Yang S; He X; Zhou S; Du X; Yi Y; Lin J; Shi Y
Target Oncol; 2020 Apr; 15(2):221-230. PubMed ID: 32239385
[TBL] [Abstract][Full Text] [Related]
35. An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.
Flümann R; Rehkämper T; Nieper P; Pfeiffer P; Holzem A; Klein S; Bhatia S; Kochanek M; Kisis I; Pelzer BW; Ahlert H; Hauer J; da Palma Guerreiro A; Ryan JA; Reimann M; Riabinska A; Wiederstein J; Krüger M; Deckert M; Altmüller J; Klatt AR; Frenzel LP; Pasqualucci L; Béguelin W; Melnick AM; Sander S; Montesinos-Rongen M; Brunn A; Lohneis P; Büttner R; Kashkar H; Borkhardt A; Letai A; Persigehl T; Peifer M; Schmitt CA; Reinhardt HC; Knittel G
Blood Cancer Discov; 2021 Jan; 2(1):70-91. PubMed ID: 33447829
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
Lee JH; Jeong H; Choi JW; Oh H; Kim YS
Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
[TBL] [Abstract][Full Text] [Related]
37. Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis.
Mi M; Liu Z; Zheng X; Wen Q; Zhu F; Li J; Mungur ID; Zhang L
Leuk Res; 2021 Dec; 111():106693. PubMed ID: 34455197
[TBL] [Abstract][Full Text] [Related]
38. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL; van Eijk R; Böhringer S; van Wezel T; Raghoo R; Ruano D; Jansen PM; Briaire-de Bruijn I; de Groot FA; Kleiverda K; Te Boome L; Terpstra V; Levenga H; Nicolae A; Posthuma EFM; Focke-Snieders I; Hardi L; den Hartog WCE; Bohmer LH; Hogendoorn PCW; van den Berg A; Diepstra A; Nijland M; Lugtenburg PJ; Kersten MJ; Pals ST; Veelken H; Bovée JVMG; Cleven AHG; Vermaat JSP
Blood Adv; 2021 Oct; 5(19):3760-3775. PubMed ID: 34478526
[TBL] [Abstract][Full Text] [Related]
39. Utility of reverse transcriptase - Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO).
Dcunha N; Sakhti D; Sigamani E; Chandramohan J; Korula A; George B; Manipadam MT; Pai R
Indian J Pathol Microbiol; 2023; 66(4):714-719. PubMed ID: 38084521
[TBL] [Abstract][Full Text] [Related]
40. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
